The influence of administration of epoetin beta pegol (CERA) and saccharated ferric oxide on erythroferron and hepcidin of hemodialyzed patients

The influence of administration of epoetin beta pegol (CERA) and saccharated ferric oxide on erythroferron and hepcidin of hemodialyzed patients - CERA and erythroferron, hepcidin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016552

Enrollment

Registered

2015-02-25

Start date

2015-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialyzed patients with renal anemia

Interventions

Intravenous administration of iron

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Maintenance hemodialyzed patients who are administrated erythropoiesis stimulating agents

Exclusion criteria

Exclusion criteria: Inflammation, iron excess, malignancy and gastro-intestinal, hepatic, and bone marrow diseases

Design outcomes

Primary

Measure	Time frame
Erythropoiesis: Hb, reticulocytes, CHr Iron metabolism: serum iron, UIBC, ferritin, erythroferron et al.	—

Countries

Japan

Contacts

Public ContactYukiko Hasuike

Hyogo College of Medicine Dep Internal Medicine, Div Kidney and Dialysis

jin@hyo-med.ac.jp0798456521

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026